Nocturnal gastroesophageal reflux disease: Issues, implications, and management strategies

Reviews in Gastroenterological Disorders

Volumn 8, Issue 2, 2008, Pages 98-108

  Johnson, David A ^a   Katz, Philip O ^b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Gastroesophageal reflux disease; GERD complications; GERD treatment; GERD related quality of life; Medical therapy of GERD; Nocturnal GERD

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECONOMIC ASPECT; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOW DRUG DOSE; MORNING DOSAGE; PRODUCTIVITY; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SLEEP;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; OMEPRAZOLE; POSTPRANDIAL PERIOD; PROTON PUMP INHIBITORS; QUALITY OF LIFE; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 46749088691     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-956.
2. A Gallup survey on heartburn across America. Princeton, NJ: The Gallup Organization; 1988.
3. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45-52.
4. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-1493.
5. Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol. 1994;89:509-512.
6. Dean BB, Aguilar D, Johnson LF, et al. Night-time and daytime atypical manifestations of gastrooesophageal reflux disease: frequency, severity and impact on health-related quality of life. Aliment Pharmacol Ther. 2008;27:327-337.
7. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology. 1992;102:109-118.
8. Feldman M, Harford WV, Fisher RS, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(4-)-ATPase inhibitor: a controlled, double-blind study. The Lansoprazole Study Group. Am J Gastroenterol. 1993;88:1212-1217.
9. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91:1749-1757.
10. Richter JE, Kahrilas PJ, Sontag SJ, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001;96:3089-3098.
11. Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999;13:49-57.
12. Pace F, Annese V, Prada A, et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741-750.
13. Bochenek WJ, Mack ME, Fraga PD, et al. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther. 2004;20:1105-1114.
14. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol. 2000;95:3071-3080.
15. Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol. 2000;12:889-897.
16. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol. 1996;91:1758-1765.
17. Metz DC, Bochenek WJ. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther. 2003;17: 155-164.
18. Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20:567-575.
19. Richter JE, Kovacs TO, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795-804.
20. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160: 1803-1809.
21. Miner P, Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332-1339.
22. Johanson J, Miner P, Jokubaitis L, et al. Rabeprazole significantly improves heartburn vs placebo in endoscopically negative GERD patients with moderate to severe symptoms. Am J Gastroenterol. 2001;96(suppl):S18.
23. Kahrilas PJ, Miner P, Johanson J, et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50:2009-2018.
24. Chey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest. 2003;23:69-84.
25. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:1914-1922.
26. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14:1249-1258.
27. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656-665.
28. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
29. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive esophagitis. Aliment Pharmacol Ther. 2005;21: 455-463.
30. Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51:852-857.
31. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51:844-850.
32. Vakil N, Guda N, Partington S. The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. Aliment Pharmacol Ther. 2006;23:649-653.
33. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastrooesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79-94.
34. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004;16:441-443.
35. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Aliment Pharmacol Ther. 2002;27:202-206.
36. Adachi K, Fujishiro H, Katsube T, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol. 2001;16:1191-1196.
37. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
38. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther. 2007;25:487-500.
39. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104:252-258.
40. Orr WC, Heading R, Johnson LF, et al. Review article: sleep and its relationship to gastrooesophageal reflux. Aliment Pharmacol Ther. 2004;20(suppl 9):39-46.
41. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24:259-272.
42. Wahlqvist P, Karlsson M, Johnson DA, et al. Relationship between symptom load of gastrooesophageal reflux disease and health-related quality of life, resource utilization, and concomitant disease: survey of a U.S. cohort. Aliment Pharmacol Ther. 2008;27:960-970.
43. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200.
44. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther. 2004;19:1105-1110.
45. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709-714.
46. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335-1339.
47. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
48. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25: 197-205.
49. Hunt RH, Armstrong D, Yaghoobi M, et al. Inhibition of acid secretion by a novel proton pump inhibitor [abstract]. Gastroenterology. 2007;132: A-486. Abstract T1190.
50. Hunt RH, Armstrong D, Yaghoobi M, et al. S-tenatoprazole-Na 30 mg, 60 mg and 90 mg versus esomeprazole (ESO) 40 mg in healthy male volunteers (hmv) [abstract]. Gastroenterology. 2007;132:A-488. Abstract T1201.
51. Zhang W, Wu J-T, Atkinson S. Pharmacokinetic (PK), pharmacodynamic (PD), and safety of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release Tak-390 (Tak-390mr) and 30 mg oral doses of lansoprazole (Lan) in healthy subjects [abstract]. Gastroenterology. 2007;132:A-487. Abstract T1194.
52. Sharma P, Shaheen NJ, Perez MC, et al. Tak-390ME, a proton pump inhibitor (PPI) with novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE): data from two randomized clinical trials [abstract]. Gastroenterology. 2008;134:A171. Abstract S1073.
53. Metz DC, Howden CW, Perez MC, et al. Tak-390MR, a proton pump inhibitor (PPI) with novel dual delayed release (DDR) formulation, maintains healing and controls heartburn in GERD patients with healed erosive esophagitis [abstract]. Gastroenterology. 2008;134:A171. Abstract S1074.